Pfizer, Inc. (PFE) is listed on NYSE in the Healthcare sector Β· Drug Manufacturers - General industry. The current price is 28.73, down -0.99% from the previous close. Market cap is approximately $163.8B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
PFE's 37.81x P/E is in premium territory. Justifiable while growth accelerates, but this is also the band that reacts first to guidance cuts or macro shocks.
ROE of 5.01% is below average. Distinguish between structural reasons (capital-intensive industry) and cyclical earnings weakness.
D/E of 74.25 indicates high leverage. Watch interest coverage and free cash flow closely, especially across rate cycles.
PFE's 2.60% revenue growth is modest. In this band, buybacks and dividends often drive most of the EPS and total return.
Pfizer, Inc.'s 5.93% yield meaningfully exceeds the market median. Confirm free cash flow comfortably covers the dividend (payout ratio under 70-80%).
Pharma and biotech are typically valued through risk-adjusted NPV/DCF on the pipeline.
Pfizer, Inc. is near its 52-week high (29.21), in the top 8% of the range. Prices close to new highs invite two readings β little overhead supply, or stretched expectations β and volume is the usual tiebreaker.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The stock moved within a 2.71% high-to-low band on the day, closing -0.99%. That falls within a typical intraday range.
Pfizer, Inc. (PFE) is listed on NYSE, with recent volume of 13,198,579 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.